Drug Delivery Formulation Using Temperature-Sensitive Hydrogel
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug delivery systems using granules often experience initial burst release, leading to inconsistent drug distribution and toxicity issues, and existing methods for controlling drug release are either ineffective or economically limited.
Innovation Solution
A drug delivery formulation comprising a granule with a biodegradable polymer and a temperature-sensitive hydrogel, where the drug is entrapped in the granule and mixed with a temperature-sensitive hydrogel to control the initial release and maintain a constant release rate over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional granule preparation methods are used, then the drug delivery system is simple to manufacture, but the initial burst release occurs leading to inconsistent drug distribution and toxicity
Solution Approach 1:
The patent uses a composite material system consisting of a biodegradable polymer matrix combined with a temperature-sensitive hydrogel. The hydrogel component responds to temperature changes to modulate drug release, creating a composite system that prevents initial burst release while maintaining manufacturing feasibility through a single-step preparation process.
Solution Approach 2:
The patent exploits temperature as a critical parameter to control drug release behavior. The temperature-sensitive hydrogel undergoes phase transition or conformational changes in response to temperature variations, enabling controlled modulation of drug release rate and preventing excessive initial burst while maintaining consistent release over time.
2Reliability
If two or more polymers with different degradation rates are mixed to control release, then the initial and subsequent release rates can be adjusted, but the faster-degrading polymer affects the slower-degrading polymer, increasing overall degradation rate and making release control difficult
Solution Approach 1:
The temperature-sensitive hydrogel acts as an intermediary component between the biodegradable polymer matrix and the external environment. It mediates the drug release process by responding to temperature stimuli, thereby controlling the release rate without being affected by the degradation of the biodegradable polymer, thus avoiding the相互 interference problem of polymer blends.
3Reliability
If the initial release is reduced by adjusting preparation parameters, then the initial burst is minimized, but the drug is not released initially or consistent release is not achieved
Solution Approach 1:
The patent introduces dynamic control of drug release through the temperature-sensitive hydrogel, which can adjust its release characteristics in response to temperature changes. This dynamic system allows the formulation to provide appropriate initial release when needed while maintaining consistent release over time, overcoming the static limitations of conventional granule systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively prevents initial burst release, maintaining a consistent drug concentration in the bloodstream for a prolonged period, thereby maximizing therapeutic effects and reducing toxicity.
Implementation Method 1
a temperature-sensitive hydrogel
Implementation Method 2
a granule containing a biodegradable polymer and a drug
Data Source
AI summary
Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time.